Abstract
To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
Original language | English |
---|---|
Pages (from-to) | 63-68 |
Number of pages | 6 |
Journal | Japanese Journal of Antibiotics |
Volume | 49 |
Issue number | 2 |
Publication status | Published - 02-1996 |
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method'. Together they form a unique fingerprint.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method. / Saito, Atsushi; Sakamoto, Mitsuo; Saito, Akira; Ohmichi, Mitsuhide; Hiraga, Yohmei; Kikuchi, Kenjiro; Ohsaki, Yoshinobu; Sasaki, Nobuhiro; Matsumoto, Hiroyuki; Suda, Toshihiro; Tsuzino, Moriyasu; Hirai, Yuichi; Inoue, Hiroshi; Yoshida, Masami; Mouri, Takashi; Kobayashi, Hitoshi; Chiba, Shinichi; Ito, Takashi; Moriya, Katsuyoshi; Bando, Takeshi; Takeuchi, Kenichi; Tanifuji, Yukio; Shirato, Kunio; Tanno, Yasuo; Takahashi, Makoto; Sakamoto, Masahiro; Nukiwa, Toshihiro; Watanabe, Akira; Sato, Kazuo; Homma, Mitsunobu; Ito, Nobuo; Yanase, Kenji; Dote, Kunio; Ohishi, Akira; Fukuda, Kiyoshi; Katsu, Masataka; Sakai, Osamu; Shiba, Kohya; Kobayashi, Hiroyuki; Sakayori, Susumu; Miura, Hiroshi; Watanabe, Hidehiro; Shimada, Kaoru; Oka, Shinichi; Sugiyama, Hirotaka; Inamatsu, Takashi; Sano, Yasuyuki; Arai, Yasuo; Otomo, Mamoru; Sukou, Matsunobu; Kobayashi, Hideo; Sikata, Susumu; Shishido, Harumi; Tsuchihashi, Keiko; Nakata, Koichiro; Tsuboi, Eiyasu; Nakatani, Tatsuo; Nakamori, Yoshitaka; Hayashi, Izumi; Koyama, Masaru; Okubo, Takao; Tani, Kenji; Kaneko, Tamotsu; Matsumura, Masanori; Takagi, Shigeto; Hasegawa, Hideyuki; Numata, Hiroyuki; Fukuda, Tsutomu; Irimajiri, Shoichiro; Matsuoka, Yasuo; Obana, Mitsuo; Matsumoto, Fumio; Sakurai, Iwao; Odagiri, Shigeki; Takahashi, Kenichi; Suzuki, Kaneo; Arakawa, Masaaki; Wada, Koichi; Iwata, Fumihide; Shimazu, Yoshinori; Sega, Hiroyuki; Tsukada, Hiroki; Kawashima, Takashi; Aoki, Nobuki; Suzuki, Yasutoshi; Sekine, Osamu; Sato, Atsuhiko; Nakano, Yutaka; Tamura, Ryoji; Suganuma, Hideki; Shirai, Masahiro; Kawakatsu, Sumio; Watanabe, Takayoshi; Akiyama, Jinichiro; Yagi, Takeshi; Torikai, Katsutaka; Fukaya, Syusaku; Mizutani, Akiei; Takeuchi, Toshihiko; Yamada, Yasuo; Hanaki, Hidekazu; Kawakami, Makoto; Hayashi, Yoshimitsu; Tashiro, Tomoyuki; Nomura, Ryuji; Takagi, Kenzo; Noda, Yasunobu; Gonda, Hideo; Taniguchi, Hiroyuki; Izumi, Saburo; Kuze, Fumiyuki; Niimi, Akio; Mochizuki, Yosiro; Nakahara, Yasuji; Kawamura, Tetsuji; Kishimoto, Tadamitsu; Tanio, Yoshiro; Igarashi, Tsuyoshi; Komuta, Kiyoshi; Ito, Masami; Okumoto, Takeshi; Mori, Masahide; Jozaki, Kiyoshi; Yonezu, Seibun; Miki, Fumio; Higashino, Kazuya; Nakano, Takashi; Miyake, Mitsutomi; Nishian, Toshihiko; Iida, Shinichiro; Yamamoto, Sayaka; Maebo, Akio; Yoshimoto, Takahiko; Sonoda, Takashi; Nakagawa, Masakiyo; Hirabayashi, Masataka; Togawa, Naoki; Yoshida, Masao; Kawai, Yoshitaka; Soejima, Rinzo; Okimoto, Niro; Matsushima, Toshiharu; Kimura, Makoto; Yamakido, Michio; Ishioka, Shinichi; Kuwahara, Masao; Mochizuki, Nobuhiro; Miyazawa, Teruomi; Doi, Masao; Arita, Kenichi; Daido, Kazuhiro; Ejima, Tsuyoshi; Sawae, Yoshiro; Takaki, Koji; Yoshida, Minoru; Aritomi, Takamichi; Oizumi, Kotaro; Ichikawa, Yoichiro; Shiraishi, Tsuneaki; Mitsutake, Yoshiyuki; Tanaka, Fumio; Ohtsuka, Takaoki; Kawahara, Masashi; Kawaguchi, Shinzo; Kawayama, Tomotaka; Sato, Yoshihiro; Honda, Yoshiaki; Ishibashi, Tsuneo; Takamoto, Masahiro; Kajiki, Akira; Harada, Yasuko; Ando, Masayuki; Suga, Moritaka; Tokunaga, Katsumasa; Shima, Kiyoshi; Takenaka, Shinobu; Hara, Kohei; Kohno, Shigeru; Kaku, Mitsuo; Koga, Nobuhiro; Inoue, Yuichi; Yamasita, Yuko; Sakata, Shingo; Fujii, Takeshi; Irifune, Kenji; Shimoguchi, Kazunori; Miyazaki, Yoshitsugu; Matsumoto, Keizo; Nagatake, Tsuyoshi; Takasugi, Masakazu; Fujishita, Mikio; Nasu, Masaru; Yamasaki, Tohru; Goto, Yoichiro; Nakama, Kaoru; Inoue, Soichi; Matsukura, Shigeru; Mashimoto, Hideo; Mukae, Hiroshi; Saito, Atsushi; Fukuhara, Hiroshi; Oyakawa, Tominori; Deguchi, Koichi; Nakashima, Mitsuyoshi.
In: Japanese Journal of Antibiotics, Vol. 49, No. 2, 02.1996, p. 63-68.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method
AU - Saito, Atsushi
AU - Sakamoto, Mitsuo
AU - Saito, Akira
AU - Ohmichi, Mitsuhide
AU - Hiraga, Yohmei
AU - Kikuchi, Kenjiro
AU - Ohsaki, Yoshinobu
AU - Sasaki, Nobuhiro
AU - Matsumoto, Hiroyuki
AU - Suda, Toshihiro
AU - Tsuzino, Moriyasu
AU - Hirai, Yuichi
AU - Inoue, Hiroshi
AU - Yoshida, Masami
AU - Mouri, Takashi
AU - Kobayashi, Hitoshi
AU - Chiba, Shinichi
AU - Ito, Takashi
AU - Moriya, Katsuyoshi
AU - Bando, Takeshi
AU - Takeuchi, Kenichi
AU - Tanifuji, Yukio
AU - Shirato, Kunio
AU - Tanno, Yasuo
AU - Takahashi, Makoto
AU - Sakamoto, Masahiro
AU - Nukiwa, Toshihiro
AU - Watanabe, Akira
AU - Sato, Kazuo
AU - Homma, Mitsunobu
AU - Ito, Nobuo
AU - Yanase, Kenji
AU - Dote, Kunio
AU - Ohishi, Akira
AU - Fukuda, Kiyoshi
AU - Katsu, Masataka
AU - Sakai, Osamu
AU - Shiba, Kohya
AU - Kobayashi, Hiroyuki
AU - Sakayori, Susumu
AU - Miura, Hiroshi
AU - Watanabe, Hidehiro
AU - Shimada, Kaoru
AU - Oka, Shinichi
AU - Sugiyama, Hirotaka
AU - Inamatsu, Takashi
AU - Sano, Yasuyuki
AU - Arai, Yasuo
AU - Otomo, Mamoru
AU - Sukou, Matsunobu
AU - Kobayashi, Hideo
AU - Sikata, Susumu
AU - Shishido, Harumi
AU - Tsuchihashi, Keiko
AU - Nakata, Koichiro
AU - Tsuboi, Eiyasu
AU - Nakatani, Tatsuo
AU - Nakamori, Yoshitaka
AU - Hayashi, Izumi
AU - Koyama, Masaru
AU - Okubo, Takao
AU - Tani, Kenji
AU - Kaneko, Tamotsu
AU - Matsumura, Masanori
AU - Takagi, Shigeto
AU - Hasegawa, Hideyuki
AU - Numata, Hiroyuki
AU - Fukuda, Tsutomu
AU - Irimajiri, Shoichiro
AU - Matsuoka, Yasuo
AU - Obana, Mitsuo
AU - Matsumoto, Fumio
AU - Sakurai, Iwao
AU - Odagiri, Shigeki
AU - Takahashi, Kenichi
AU - Suzuki, Kaneo
AU - Arakawa, Masaaki
AU - Wada, Koichi
AU - Iwata, Fumihide
AU - Shimazu, Yoshinori
AU - Sega, Hiroyuki
AU - Tsukada, Hiroki
AU - Kawashima, Takashi
AU - Aoki, Nobuki
AU - Suzuki, Yasutoshi
AU - Sekine, Osamu
AU - Sato, Atsuhiko
AU - Nakano, Yutaka
AU - Tamura, Ryoji
AU - Suganuma, Hideki
AU - Shirai, Masahiro
AU - Kawakatsu, Sumio
AU - Watanabe, Takayoshi
AU - Akiyama, Jinichiro
AU - Yagi, Takeshi
AU - Torikai, Katsutaka
AU - Fukaya, Syusaku
AU - Mizutani, Akiei
AU - Takeuchi, Toshihiko
AU - Yamada, Yasuo
AU - Hanaki, Hidekazu
AU - Kawakami, Makoto
AU - Hayashi, Yoshimitsu
AU - Tashiro, Tomoyuki
AU - Nomura, Ryuji
AU - Takagi, Kenzo
AU - Noda, Yasunobu
AU - Gonda, Hideo
AU - Taniguchi, Hiroyuki
AU - Izumi, Saburo
AU - Kuze, Fumiyuki
AU - Niimi, Akio
AU - Mochizuki, Yosiro
AU - Nakahara, Yasuji
AU - Kawamura, Tetsuji
AU - Kishimoto, Tadamitsu
AU - Tanio, Yoshiro
AU - Igarashi, Tsuyoshi
AU - Komuta, Kiyoshi
AU - Ito, Masami
AU - Okumoto, Takeshi
AU - Mori, Masahide
AU - Jozaki, Kiyoshi
AU - Yonezu, Seibun
AU - Miki, Fumio
AU - Higashino, Kazuya
AU - Nakano, Takashi
AU - Miyake, Mitsutomi
AU - Nishian, Toshihiko
AU - Iida, Shinichiro
AU - Yamamoto, Sayaka
AU - Maebo, Akio
AU - Yoshimoto, Takahiko
AU - Sonoda, Takashi
AU - Nakagawa, Masakiyo
AU - Hirabayashi, Masataka
AU - Togawa, Naoki
AU - Yoshida, Masao
AU - Kawai, Yoshitaka
AU - Soejima, Rinzo
AU - Okimoto, Niro
AU - Matsushima, Toshiharu
AU - Kimura, Makoto
AU - Yamakido, Michio
AU - Ishioka, Shinichi
AU - Kuwahara, Masao
AU - Mochizuki, Nobuhiro
AU - Miyazawa, Teruomi
AU - Doi, Masao
AU - Arita, Kenichi
AU - Daido, Kazuhiro
AU - Ejima, Tsuyoshi
AU - Sawae, Yoshiro
AU - Takaki, Koji
AU - Yoshida, Minoru
AU - Aritomi, Takamichi
AU - Oizumi, Kotaro
AU - Ichikawa, Yoichiro
AU - Shiraishi, Tsuneaki
AU - Mitsutake, Yoshiyuki
AU - Tanaka, Fumio
AU - Ohtsuka, Takaoki
AU - Kawahara, Masashi
AU - Kawaguchi, Shinzo
AU - Kawayama, Tomotaka
AU - Sato, Yoshihiro
AU - Honda, Yoshiaki
AU - Ishibashi, Tsuneo
AU - Takamoto, Masahiro
AU - Kajiki, Akira
AU - Harada, Yasuko
AU - Ando, Masayuki
AU - Suga, Moritaka
AU - Tokunaga, Katsumasa
AU - Shima, Kiyoshi
AU - Takenaka, Shinobu
AU - Hara, Kohei
AU - Kohno, Shigeru
AU - Kaku, Mitsuo
AU - Koga, Nobuhiro
AU - Inoue, Yuichi
AU - Yamasita, Yuko
AU - Sakata, Shingo
AU - Fujii, Takeshi
AU - Irifune, Kenji
AU - Shimoguchi, Kazunori
AU - Miyazaki, Yoshitsugu
AU - Matsumoto, Keizo
AU - Nagatake, Tsuyoshi
AU - Takasugi, Masakazu
AU - Fujishita, Mikio
AU - Nasu, Masaru
AU - Yamasaki, Tohru
AU - Goto, Yoichiro
AU - Nakama, Kaoru
AU - Inoue, Soichi
AU - Matsukura, Shigeru
AU - Mashimoto, Hideo
AU - Mukae, Hiroshi
AU - Saito, Atsushi
AU - Fukuhara, Hiroshi
AU - Oyakawa, Tominori
AU - Deguchi, Koichi
AU - Nakashima, Mitsuyoshi
N1 - Copyright: Copyright 2005 Elsevier B.V., All rights reserved.
PY - 1996/2
Y1 - 1996/2
N2 - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
AB - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=29344459609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29344459609&partnerID=8YFLogxK
M3 - Review article
C2 - 8721077
AN - SCOPUS:29344459609
VL - 49
SP - 63
EP - 68
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
SN - 0368-2781
IS - 2
ER -